Embecta Corp. (EMBC) to Issue Quarterly Dividend of $0.01 on June 15th

by · The Cerbat Gem

Embecta Corp. (NASDAQ:EMBC – Get Free Report) announced a quarterly dividend on Friday, May 1st. Shareholders of record on Thursday, May 28th will be paid a dividend of 0.01 per share on Monday, June 15th. This represents a c) annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 28th.

Embecta has a dividend payout ratio of 1.4% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Embecta to earn $1.75 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.3%.

Embecta Price Performance

Shares of EMBC stock opened at $3.32 on Tuesday. Embecta has a 12-month low of $2.77 and a 12-month high of $15.55. The firm has a market capitalization of $196.98 million, a price-to-earnings ratio of 1.75 and a beta of 1.09. The firm has a fifty day moving average of $7.33 and a 200-day moving average of $10.16.

Embecta (NASDAQ:EMBC – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). The firm had revenue of $221.80 million during the quarter, compared to the consensus estimate of $235.67 million. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The firm’s revenue for the quarter was down 14.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 earnings per share. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Research analysts expect that Embecta will post 1.62 earnings per share for the current year.

About Embecta

(Get Free Report)

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

Read More